Program
VK2735
A development code. Also written as “VK2735 Drug” and “VK2735 Oral”.
Its studies are mostly in Weight Loss · Overweight, led by Viking Therapeutics.
Furthest: phase 3, since Jul 29, 20258 company-led studies, 5 open or runningNext primary completion: May 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viking Therapeutics | 85 open or running | phase 3since Jul 29, 2025 | Jan 10, 2022 | May 2027phase 1 · NCT07838740 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 10, 2022First study: phase 1 study in Weight LossFirst studyNCT05203237 · 92 enrolled · Australia
- Sep 28, 2023Phase 2 study in Weight LossNCT06068946 · 176 enrolled · United States
- Feb 10, 2025Phase 2 study in Weight LossNCT06828055 · 280 enrolled · United States
- Jul 29, 20252 phase 3 studies in Weight LossNCT07104500, NCT07104383
- Sep 9, 2026Phase 1 study in Weight LossNCT07838740 · 270 planned · United States
- Oct 5, 20262 phase 3 studies in Weight LossNCT07868939, NCT07868835
Ahead
- May 2027Primary completion: phase 1 study in Weight LossNCT07838740
- Jul 1, 2027Primary completion: phase 3 study in Weight LossNCT07104500
- Jul 1, 2027Primary completion: phase 3 study in Weight LossNCT07104383
- Jul 2028Primary completion: phase 3 study in Weight LossNCT07868835
TargetBeta
“VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 12 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| enicepatide | Hoffmann-La Roche | phase 3 | 10 |
| NNC0519-0130 | Novo Nordisk | phase 2 | 11 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07868939Weight Loss · United States | 3 | Recruiting | Oct 2028 | 560 |
| NCT07868835Weight Loss · United States | 3 | Recruiting | Jul 2028 | 560 |
| NCT07838740Weight Loss · United States | 1 | Recruiting | May 2027 | 270 |
| NCT07104500Weight Loss · United States, Puerto Rico | 3 | Active, not recruiting | Jul 1, 2027 | 4,500 |
| NCT07104383Weight Loss · United States, Puerto Rico | 3 | Active, not recruiting | Jul 1, 2027 | 1,100 |
| NCT06828055Weight Loss · United States | 2 | Completed | Jun 24, 2025 | 280 |
| NCT06068946Weight Loss · United States | 2 | Completed | Feb 27, 2024 | 176 |
| NCT05203237Weight Loss · Australia | 1 | Completed | Nov 4, 2024 | 92 |
How it is read
Names in the registry
- “VK2735”, 6 entries
- “VK2735 Drug”, 2 entries
- “VK2735 Oral”, 1 entry
Codes read as this program: VK2735.
Conditions, from the studies’ own filings
- Weight Loss, 7 studies
- Overweight, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.